Cargando…

Expression and Clinical Significance of Various Checkpoint Molecules in Advanced Osteosarcoma: Possibilities for Novel Immunotherapy

OBJECTIVES: The fact that studies on anti‐programmed cell death 1 (PD‐1) or its relevant ligand 1 (PD‐L1) have yielded such few responses greatly decreases the confidence in immunotherapy with checkpoint inhibitors for advanced osteosarcoma. We intended to characterize the expression of various chec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Lu, Chen, Chenglong, Liang, Xin, Xu, Jie, Sun, Xin, Sun, Kunkun, Yang, Rongli, Tang, Xiaodong, Guo, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977595/ https://www.ncbi.nlm.nih.gov/pubmed/36519392 http://dx.doi.org/10.1111/os.13620

Ejemplares similares

Anorexia, Hypertension, Pneumothorax, and Hypothyroidism: Potential Signs of Improved Clinical Outcome Following Apatinib in Advanced Osteosarcoma
por: Xie, Lu, et al.
Publicado: (2020)

Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
por: Xie, Lu, et al.
Publicado: (2020)

Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma
por: Xu, Jiuhui, et al.
Publicado: (2023)

Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
por: Fujimura, Taku, et al.
Publicado: (2022)

Prognostic significance and therapeutic potentials of immune checkpoints in osteosarcoma
por: Meftahpour, Vafa, et al.
Publicado: (2022)

Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02)
por: Xie, Lu, et al.
Publicado: (2023)

Quality of life and Q-TWiST were not adversely affected in Ewing sarcoma patients treated with combined anlotinib, irinotecan, and vincristine: (Peking University People's Hospital Ewing sarcoma trial-02, PKUPH-EWS-02)
por: Dong, Sen, et al.
Publicado: (2021)

Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy
por: Bazhin, Alexandr V., et al.
Publicado: (2018)

Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: A retrospective study in two centres
por: Xie, Lu, et al.
Publicado: (2021)

Nanobodies targeting immune checkpoint molecules for tumor immunotherapy and immunoimaging (Review)
por: Yu, Sheng, et al.
Publicado: (2021)

Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two‐Cohort, Phase Ib/II Trial
por: Xu, Jie, et al.
Publicado: (2021)

Apatinib for Treatment of Inoperable Metastatic or Locally Advanced Chondrosarcoma: What We Can Learn About the Biological Behavior of Chondrosarcoma from a Two-Center Study
por: Xie, Lu, et al.
Publicado: (2020)

Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy
por: Zhang, Cai, et al.
Publicado: (2020)

Complete remission of metastatic osteosarcoma using combined modality therapy: a retrospective analysis of unselected patients in China
por: Xie, Lu, et al.
Publicado: (2021)

Gain and loss from transcatheter intra-arterial limb infusion of cisplatin for extremity osteosarcoma: a retrospective study of 99 cases in the past six years
por: Xie, Lu, et al.
Publicado: (2019)

The Clinical Implications of Tumor Mutational Burden in Osteosarcoma
por: Xie, Lu, et al.
Publicado: (2021)

Nanosized drug delivery strategies in osteosarcoma chemotherapy
por: Chen, Chenglong, et al.
Publicado: (2023)

Immune checkpoint inhibitors in osteosarcoma: A hopeful and challenging future
por: Zhang, Zeng, et al.
Publicado: (2022)

Integrated analysis of single-cell and bulk RNA sequencing data reveals an immunostimulatory microenvironment in tumor thrombus of osteosarcoma
por: Ji, Tao, et al.
Publicado: (2023)

Suppressors of cytokine signaling: Potential immune checkpoint molecules for cancer immunotherapy
por: Chikuma, Shunsuke, et al.
Publicado: (2017)

Radiological characteristics and predisposing factors of venous tumor thrombus in pelvic osteosarcoma: A mono‐institutional retrospective study of 115 cases
por: Liang, Haijie, et al.
Publicado: (2018)

Novel Immunotherapies for Osteosarcoma
por: Lu, Yubao, et al.
Publicado: (2022)

Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis
por: Alifu, Muyesar, et al.
Publicado: (2023)

Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer
por: Zeng, Dongqiang, et al.
Publicado: (2021)

Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
por: Wang, Yuchen, et al.
Publicado: (2022)

Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
por: Cao, Yuqing, et al.
Publicado: (2020)

HLA-G and Other Immune Checkpoint Molecules as Targets for Novel Combined Immunotherapies
por: Morandi, Fabio, et al.
Publicado: (2022)

Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade
por: Wilkinson, Robert W., et al.
Publicado: (2018)

Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development
por: Sasikumar, Pottayil G., et al.
Publicado: (2022)

Research into the characteristic molecules significantly affecting liver cancer immunotherapy
por: Chen, Junhong, et al.
Publicado: (2023)

Macrophages in Osteosarcoma Immune Microenvironment: Implications for Immunotherapy
por: Luo, Zhong-Wei, et al.
Publicado: (2020)

B7-H3, a checkpoint molecule, as a target for cancer immunotherapy
por: Yang, Shuo, et al.
Publicado: (2020)

Advances of Osteosarcoma Models for Drug Discovery and Precision Medicine
por: Tan, Linyun, et al.
Publicado: (2023)

Small-Molecule PROTACs for Cancer Immunotherapy
por: Liu, Zefan, et al.
Publicado: (2022)

Prognostic significance of the expression of HER family members in primary osteosarcoma
por: Wang, Sheng-Lin, et al.
Publicado: (2018)

Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy
por: Xie, Guozhu, et al.
Publicado: (2018)

LncRNA TUG1 promotes the development of osteosarcoma through RUNX2
por: Sheng, Kunkun, et al.
Publicado: (2019)

The biological function and clinical significance of STIL in osteosarcoma
por: Ji, Shu-fan, et al.
Publicado: (2021)

Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma
por: Qi, Xinmeng, et al.
Publicado: (2017)

Response Prediction in Immune Checkpoint Inhibitor Immunotherapy for Advanced Hepatocellular Carcinoma
por: Hung, Hao-Chien, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_piliuj7bj0f9fj8e5entjq03qu